RxDoctor Payments Data

Domingo Rodriguez, MD

Internal Medicine · San Juan, PRNPI 1376649749

Payments from drug & device makers

$742in general payments, 2019–2025

Across 23 payments — averaging $32.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$322
  • Sanofi-aventis U.S. LLC$200
  • PBG Puerto Rico LLC$78
  • E.r. Squibb & Sons, L.L.C.$55
  • AbbVie$35
  • Merck$28
  • plus $24 from 1 others

What the payments were for

  • Speaking & faculty fees$20027%
  • Food & beverage$54273%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca12$322
Sanofi-aventis U.S. LLC1$200
PBG Puerto Rico LLC4$78
E.r. Squibb & Sons, L.L.C.2$55
AbbVie1$35
Merck2$28
Johnson & Johnson1$24

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$742 in reported general payments places this provider in the 50th percentile of 1,043 internal medicine providers in Puerto Rico.

See all internal medicine providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$7,899
Medicare patients
29
Services billed
116

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban45$32,559
Xigduo XrDapaglifloz Propaned/Metformin40$31,423
FarxigaDapagliflozin Propanediol49$30,112
SynthroidLevothyroxine Sodium354$27,239
JanumetSitagliptin Phos/Metformin Hcl34$25,675
XareltoRivaroxaban26$21,544
TrulicityDulaglutide12$12,072
Candesartan Cilexetil111$8,619
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate27$6,387
Candesartan-HydrochlorothiazidCandesartan/Hydrochlorothiazid63$6,222
Gabapentin478$5,945
Humalog Mix 75-25Insulin Lispro Protamin/Lispro19$4,885
LantusInsulin Glargine,hum.Rec.Anlog41$4,096
Rosuvastatin Calcium266$3,613
Atorvastatin Calcium357$3,564

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Symbicort$322$32,67960 claims
AbbVieSynthroid$35$27,239354 claims
MerckJanumet$28$25,67534 claims
Johnson & JohnsonXarelto$24$21,54426 claims
Sanofi-aventis U.S. LLCLantus$200$4,09641 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,043 internal medicine providers in Puerto Rico.

Other internal medicine in San Juan

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →